Research Article - (2019) Volume 16, Issue 4

The Role Played by Salicylic Acid and Omega 3 in the Placental Vascular Resistance Mechanism: A Pilot Study
Alice Campos Batista1, Barbara Caetano Ribeiro1, Bia Drummond Paiva1, La�?­s Mapa de Brito Fernandes1, Luiza Cotta Xavier1, Maria Paula Ferreira Arcuri1, Clarissa Rocha Panconi2,4, Alexander Cangussu Silva2,4, Mariana Pinto Sirimarco2,4, Larissa Milani Coutinho2,4, Patr�?­cia de Oliveira Lima3,4, Gabriel Duque Pannain2,4, Iasmin Dantas Sakr Khouri2,4, Paula Silveira Mendes2,4, Miralva Aurora Galv�?£o Carvalho2,4, Paulo Henrique Barros Valente2,4, Marcus Gomes Bastos2 and Juliana Barroso Zimmermmann1,2,4*
 
1José Bonifácio Lafayette de Andrada Foundation (FUNJOBE), Medical School of Barbacena, Barbacena, Brazil
Federal University of Juiz de Fora (UFJF), Juiz de Fora, Brazil
2University Hospital (UFJF), EBSERH, Santa Catarina, Juiz de Fora, Brazil
3High Risk Prenatal Care Group, Brazil
 
*Correspondence: Juliana Barroso Zimmermmann, Federal University of Juiz de Fora (UFJF), Juiz de Fora, Brazil, Tel: +5532988483345, Email:

Received: 13-Sep-2019 Published: 30-Sep-2019, DOI: 10.35248/2090-7214.19.16.333

Abstract

Introduction: Doppler flowmetry of uterine arteries allows identifying women at risk of developing preeclampsia (PE), mainly early preeclampsia; it also facilitates the timely use of prophylaxis. Minidose Acetylsalicylic Acid (ASA) can help preventing/delaying preeclampsia development, as well as reducing its severity and the risk of complications. However, not all patients can use this medication; therefore, it is necessary finding clinical alternatives for pregnant women who do not tolerate ASA, as well as evaluating the possibility of increasing this prophylaxis with new drugsthe use of omega 3 is one of these alternatives. Thus, it is possible assuming that omega use by pregnant women could reduce the vascular resistance of uterine arteries and facilitate placentation. The aim of the current study is to evaluate uterine artery resistance and pulsatility indices, as well as bilateral notch in pregnant women presenting identifiable risk factor for PE development, who use omega 3 in association, or not, with ASA.

Methodology: The current research is a randomized-controlled, non-blind, parallel, two-arm, open-label preventive clinical trial. Patients were divided into two groups: group 1–use of ASA; and group 2-use of ASA+omega 3. Omegabased supplementations comprised doses of 400 mg/day in gelatin capsules, at DHA: EPA ratios 2.5:1 and 5.0:1.

Results: Patients’ mean age was 33.48+4.68 years. Mean pregnancies and childbirths were 1.93+1.30 and 0.59 ± 0.37, respectively. Results of uterine artery Doppler flowmetry were associated with omega and/or ASA use; patients who used ASA in association with omega (ASA+omega) recorded the highest uterine artery resistance and pulsatility indices – results were statistically significant. The comparison between ASA use in association, or not, with omega did not show difference in PE, prematurity, oligohydramnios, IUGR or hospitalization in neonatal ICU frequency. There were no cases of fetal death or Hellp Syndrome in either groups.

Conclusion: The omega 3 use in association with ASA has increased the uterine artery resistance and pulsatility indices of the investigated patients; however, it did not make any difference in primary and secondary outcomes.

Keywords

Prenatal care; Acetyl salicylic acid; Omega

Introduction

Maternal inflammatory response at placentation time may be of paramount importance to help better understanding the etiopathogenesis of a series of pathologies such as hypertensive syndromes during pregnancy. Understanding this process also means understanding that the optimal placental function can be impaired by several mechanisms such as hypertension, oxidative stress, thrombophilias and, consequently, infarcts caused by changes in placental perfusion [1].

Hypertensive conditions in the third gestational trimester may be an adaptive response of pregnant women to low uteroplacental perfusion in order to maintain adequate blood flow in the fetal compartment. Myometrial segments of uteroplacental circulation suffer severe hyperplasia and arteriosclerosis, in opposition to high resistance and peripheral pressure, a fat that changes the placentation mechanism and leads to increased hypoxia, vasospasm and oxidative stress [2-4]. The repercussion of such changes can be identified in uterine artery Doppler; they are depicted by increased resistance and pulsatility indices and by bilateral protodiastolic notch, which happens due to non-trophoblastic invasion in the myometrial segment of the spiral arteries [5].

Thus, Doppler flowmetry of uterine arteries allows identifying pregnant women at risk of developing preeclampsia (PE), mainly early preeclampsia, and it facilitates the timely use of prophylaxis, either to prevent or slow the development of the severe form of the disease. Thus, abnormal uterine artery Doppler findings in the first and second gestational trimesters have been indicated as appropriate screening tests to predict PE, intrauterine growth restriction (IUGR) and placental abruption (PA) [6-8].

Minidose acetylsalicylic acid (ASA) can help preventing/delaying preeclampsia development, as well as reducing its severity and the risk of complications. Minidose ASA can selectively inhibit the cyclooxygenase pathway in platelets, but not in the vascular endothelium; it blocks thromboxane synthesis, but not prostacyclin synthesis; it prevents vasoconstriction and pathological coagulation in the placenta. According to Trivedi et al. [9], low-dose ASA helps preventing preeclampsia in high-risk pregnant women (RR=0.79; 95% CI; 0.65-0.97), although it has no effect on low-risk pregnant women (RR=0.86; 95% CI; 0.64-1.1). These findings meet the study by Ruano et al. [10], who identified ASA protective effect against PE development in high-risk pregnant women (RR=0.87; 95% CI, 0.79-0.96), but not in low-risk pregnant women (RR=0.95; 95% CI; 0.81-1.11). According to the systematic review carried out by Henderson et al. [11], the use of low-dose ASA helps preventing preeclampsia in high-risk pregnant women (RR=0.76; 95% CI; 0.62-0.95). Another study was conducted with 1,776 pregnant women, who started taking aspirin (150 mg/day) or placebo between the 11th and 14th gestational weeks. Results have shown that aspirin has successfully reduced PE rates in comparison to the placebo (p=0.004) [12]. Based on the ASPRE trial, low-dose aspirin has successfully reduced the risk of PE development before the 32nd gestational week and before the 37th gestational week; however, it did not reduce the risk of PE development in pregnant women after the 37th gestational week [13,14]. Thus, it is possible saying that aspirin (ASA) plays a key role in the prophylaxis of women experiencing risk pregnancies [9-13].

However, not all patients can use ASA. Patients with peptic ulcers, gastritis, Chron’s disease, ulcerative colitis and ASA intolerance should not take this medication on a daily basis. In addition, aspirin does not appear to be totally harmless. Xu [15] has found increased likelihood of placental abruption in pregnant women using aspirin (OR=1.35; CI=1.05-1.73; p=0.02), as well as higher frequency of bleeding episodes (5.6 episodes/1000 patients/year). An Italian study has found that ASA increased gastrointestinal and brain bleeding [16].

It is necessary finding clinical alternatives for pregnant women who do not tolerate ASA, as well as evaluating the likelihood of increasing this prophylaxis with new drugs. Moreover, the likelihood of reducing vascular resistance, even in ASA users, appears to be a good alternative to maintain satisfactory placental flow. The use of essential fatty acids (FA) is a new perspective that seems to be applicable in daily medical practice. These fatty acids are part of lipids (or fats) and they comprise the carboxyl group (COOH). Their chains are aliphatic, i.e., they are open and seen as organic components because their molecules have carbon and hydrogen, which are produced when fats are disrupted. Among these fatty acids, one finds the alpha-linolenic (ALA-omega 3) and linoleic (LA-omega 6) acids, which are converted by enzymes such as elongases and desaturases. ALA converts into eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids, whereas LA converts into arachidonic acid (AA) [16].

Recent studies have found that fatty acids can increase blood flow in the uterine artery and, consequently, they can improve blood supply in this vessel [17]. This process happens because both DHA and EPA act to reduce prostaglandin E2 (proinflammatory) metabolite production and to decrease thromboxane A2 concentrations, which is a potent platelet aggregator and vasoconstrictor; to reduce leukotriene B4 formation, which induces inflammations, leukocyte adherence and chemotaxis; as well as to increase thromboxane A3 concentrations, which is a weak platelet aggregator and vasoconstrictor, prostacyclin PGI3 concentrations, which is a vasodilator and platelet aggregation inhibitor; and leukotriene B5 concentrations, which is a weak inflammation-inducer and chemotactic agent [17-20]. Based on a recent study, women who used DHA during pregnancy had lower chance of developing severe preeclampsia (RR 0.46; CI=0.25-0.83). On the other hand, ALA intake was associated with higher risk of developing severe preeclampsia (RR 1.71; 1.07-2.75) [21]. The truth is that although omega can, in theory, reduce the likelihood of preeclampsia development, many trials did not show this benefit. Assumingly, these differences are associated with the selected sample type, with the adopted omega dose or even with the DHA: EPA ratio in the ingested compound, as well as with the time supplementation was implemented [22]. However, studies conducted with animals have shown promising outcomes resulting from such supplementation [23].

Accordingly, it is possible assuming that DHA use by pregnant women could reduce vascular resistance in the uterine arteries and facilitate placentation. In light of the foregoing, the aim of the current study was to evaluate uterine artery resistance and pulsatility indices, as well as bilateral notch, in pregnant women presenting identifiable risk factor for PE development, who used omega 3 in association, or not, with ASA.

Patients and Methods

Methodology

The current research is a randomized-controlled, non-blind, parallel, two-arm, open-label preventive clinical trial, which comprised pregnant women who were treated in the Obstetrics services at HU-UFJF and at the Medical School of Barbacena. Patients treated in these two services were included in the current study due to the possibility of having them being assessed by the same team coordinator and of using a standard prenatal chart-in compliance with FEBRASGO standards [24]. Clinical and epidemiological data (pregnancies, miscarriages, gestational age at the beginning of prenatal care, childbirths, fetal weight, and underlying pathology) were collected during anamnesis. Primary outcome comprised high uterine artery resistance and preeclampsia, whereas secondary outcome comprised fetal weight, hospitalization in neonatal ICU, fetal death, placental abruption, Hellp syndrome and fetal death.

Pregnant women at risk of developing preeclampsia were included in the study, based on criteria set by ACOG [25] and NICE [26], which were adapted for the current study. Pregnant women at risk of developing preeclampsia comprised patients with diabetes, chronic hypertension, autoimmune or kidney diseases, thrombophilias, as well as primiparous, obese patients and women older than 35 years.

Women whose mean arterial pressure was higher than, or equal, to 100 mmHg, or whose uterine artery doppler showed notch in the first gestational trimester, were also included in the study. The presence of any of these data (anamnesis, altered blood pressure or uterine artery Doppler) was considered positive for participants’ inclusion in the study. Pregnant women who did not agree to participate in the study and the ones who did not accept the service protocol were excluded from the study, as shown in Figure 1.

clinics-mother-child-health-pregnant

Figure 1. Inclusion criteria applied to pregnant women in the current study. Any of these positive aspects was taken as inclusion criterion in the
study.

Sample calculation took into consideration the frequency of preeclampsia cases in our service-which ranged from 25% to 35% because it is a specific outpatient clinic for hypertensive diseases. The number of participants in pilot studies does not need to exceed 10% of the target sample. Based on this requirement, the minimum sample in the herein conducted pilot study comprised 40 pregnant women, who were divided into two groups: group 1- patients using ASA; and group 2 – patients using ASA+omega 3. Omega supplements were taken in the gelatin capsule form (400 mg/day) at DHA: EPA ratios 2.5:1 and 5.0:1. The adopted ratio was randomly selected based on supplement availability in the obstetric service, since it was a pilot study. ASA was formulated at the dose of 100 mg/day and patients should take it after eating, on a daily basis.

The uterine artery Doppler was carried out at the 12th gestational week and, later, between the 24th and 28th gestational weeks in order to evaluate patients’ uterine arteries. Patients were placed in supine, semi-sitting position, by keeping angles of 15° and 30° between them and the examination table to avoid vena cava compression. Next, images were generated, and Doppler mapping was performed. The transducer was longitudinally placed in the iliac fossa, parallel to the iliac crest and to the uterine wall, in order to identify the iliac vessels. A subtle medial movement enabled seeing the uterine artery that, along with the external iliac artery, formed the false image of a cross. The uterine artery was assessed 1 to 2 cm away from this point, based on pulsatility index and on notch identification. Resistance (RI) and pulsatility (PI=A-B/Mean) indices were the herein adopted hemodynamic indices.

Statistical analysis

Data were digitized in electronic Access database forms specially developed for the current study. Results were expressed as mean and standard deviation (quantitative variables) and as absolute and relative frequency (categorical variables). Statistical analyses were carried out in the Statistical Package for Social Sciences (SPSS) software, version 13.0 for Windows (Chicago, IL, USA). Student’s t-test was used to compare means between independent samples, Fischer’s exact test was used, whenever possible, to assess association. The χ2 test was used to assess variables presenting more than two categories. Significance level was set at 5%.

Ethics

The current study was submitted via plataforma Brasil (Brazil platform) to, and approved by, the Ethics Committee of the Medical School of Barbacena-José Bonifácio Lafayette Andrada Foundation-FAME–Barbacena. All patients signed the free and informed consent form after they were instructed as to the confidentiality of their identification data, as well as to the possibility of withdrawing at any time during the research, without any prejudice.

Results

Forty-seven (47) patients treated in the aforementioned obstetrics services during this period were assessed. Patients mean age was 33.5 ± 4.7 years; minimum age was 23 years and maximum age was 42 years. The mean numbers of pregnancies and childbirths were 1.93 ± 1.3 and 0.6 ± 0.4, respectively. The mean number of miscarriages was 0.6 ± 0.6.

The analysis of previous diseases found 12 patients (26.1%) with chronic hypertension, 1 patient (2.2%) with kidney disease, 4 patients (8.5%) with diabetes, and 3 patients (6.5%) with hypothyroidism.

Uterine artery resistance and pulsatility indices are shown in Table 1; they were repeated between the 24th and 28th gestational weeks, after the screening carried out in the 12th gestational week. The comparison between right and left uterine pulsatility indices did not show statistical difference between them (p=0.42), as shown in Table 1. The incidence of unilateral or bilateral uterine artery notch was investigated-unilateral notch was identified in 42.3% of patients, whereas bilateral notch was identified in 26.9% of them.

  Mean Minimum Maximum Standard deviation
Uterine artery pulsatility index in pregnant women assessed in the current study
Right Uterine Artery 1.0 0.6 2.3 0.4
Left Uterine Artery 0.9 0.3 3.6 0.7
Uterine artery resistance index in pregnant women assessed in the current study
Right Uterine Artery 0.6 0.3 1.8 0.3
Left Uterine Artery 0.9 0.3 3.6 0.9
Mean Uterine Artery Index in pregnant women assessed in the current study
Pulsatility 0.9 0.5 2.9 0.5
Resistance 0.5 0.3 1.2 0.2

Table 1: Uterine artery resistance and pulsatility indices tested between the 24th and the 28th gestational week.

Results of uterine artery Doppler flowmetry were associated with omega and/or ASA use, as shown in Table 2.

Mean uterine artery pulsatility index
  Mean Standard deviation Minimum Maximum p value F
ASA 1.0 0.3 0.6 1.7 0.01 7.57
ASA+omega 1.9 1.4 0.9 2.9
Mean uterine artery resistance index
ASA 0.5 0.1 0.3 0.7 0.01 7.25
ASA+omega 0.8 0.3 0.6 1.2    

Table 2: Pulsatility indices in the second gestational trimester of pregnant women using AAS or AAS+omega.

Patients who used ASA in association with omega (ASA+omega) recorded significantly higher resistance and pulsatility indices (p=0.01). The comparison between right and left uterine arteries did not show statistically significant results (p=0.58). However, the evaluation of omega concentrations (DHA/EPA ratio) in the formulation has shown that pulsatility indices recorded the lowest values when the highest DHA/EPA ratio (5:1) was adopted, as shown in Table 3, although without statistical significance. The association between notch incidence and ASA or ASA+omega use did not show statistically significant difference between treatments (p=0.6).

(DHA/ EPA) Concentration Mean p value T
Right uterine artery pulsatility index
(2.5:1) 1.2 ± 0.8 0.35 0.95
(5:1) 0.85 ± 0.4
Left uterine artery pulsatility index
(2.5:1) 1.4 ±1.4 0.31 1.2
(5:1) 0.7 ± 0.2
Mean uterine artery pulsatility index
(2.5:1) 1.3 ± 1.1 0.23 1.6
(5:1) 0.7 ± 0.09
Mean uterine artery resistance index
(2.5:1) 0.5 ± 0.2 0.72 0.12
(5:1) 0.5 ± 0.2
Right uterine artery resistance index
(2.5:1) 0.5 ± 0.2 0.72 0.12
(5:1) 0.6 ± 0.5
Left uterine artery resistance index
(2.5:1) 0.5 ± 0.1 0.6 0.31
(5:1) 0.5 ± 0.2

Table 3: Pulsatility and resistance indices in the second gestational trimester and their association with the DHA:EPA ratio used by pregnant women.

The comparison between ASA use in association, or not, with omega did not show differences in PE (p=0.3), prematurity (p=0.9), oligohydramnios (p=0.1), IUGR (p=0.9) or hospitalization in neonatal ICU (p=0.9) frequency. There was no case of fetal death or Hellp Syndrome in either group. Based on the neonatal weight comparison, the weight of babies born from mothers treated with omega+ASA (3,167.5 ± 95.5 g) was significantly higher (p=0.9) than that of babies born from mothers treated only with ASA (3,109.0 ± 480.9).

Discussion

Optimal placental function can be impaired by many mechanisms such as hypertension, oxidative stress, thrombophilias and, consequently, the incidence of infarctions [1-3]. Myometrial segments of uteroplacental circulation suffer severe hyperplasia and arteriosclerosis due to high resistance and peripheral pressure, a fact that impairs placentation and leads to hypoxia, vasospasm and oxidative stress [1-5]. The uterine artery Doppler investigation allows identifying these changes based on increased resistance and pulsatility indices and on the incidence of bilateral protodiastolic notch, which happens due to nontrophoblastic invasion in the myometrial segment of the spiral arteries [1-5].

The aim of the current study was to evaluate vascular resistance in pregnant women treated with ASA+omega in comparison to pregnant women treated only with ASA, since previous studies have already found increased uterine artery flow and, consequently, satisfactory blood supply in these patients. By acting as substrate for the synthesis of anti-inflammatory mediators, they positively changed thromboxane and prostaglandin E2 production, which would hypothetically contribute to longer gestational periods, higher birth weight, lower risk of preeclampsia development and to the birth of newborns small for their gestational age [22]. However, not all studies have evaluated high-risk pregnancies and many of them did not find effects beneficial enough to enable generalizing the use of these drugs by all pregnant women [27,28]. Other studies have evaluated specific groups of pregnant women such as smokers. In this case, omega-3 supplementation was associated with lower risk of spontaneous preterm birth in smokers (RR=0.56; 95% CI; 0.36-0.87) than in nonsmokers (RR=1.04; 95% CI; 0.84-1.29). In addition, low birth weight was less often diagnosed in babies born from smokers subjected to omega-3 supplementation (RR=0.57, 95% CI 0.36-0.90) than in babies born from nonsmokers (RR=0.93; 95% CI; 0.71-1.24) [29].

Although, in theory, omega 3 can decrease the likelihood of preeclampsia development, several studies did not show this effect. Assumingly, these differences are associated with the selected samples, with the adopted omega dose or even with the DHA: EPA ratio in the ingested compound, as well as with the time when compound supplementation was introduced [22]. Apparently, although the omega+ASA association led to higher uterine artery pulsatility and resistance indices, results in the current study were contradictory because there was not increase in the frequency of preeclampsia, in low birth weight or in any other unfavorable outcome. Actually, babies born from pregnant women treated with omega+ASA presented increased birthweight, although it was not statistically significant.

These apparently contradictory findings may be associated with the adopted intervention, since the omega-3 drug combination comprised both EPA and DHA. Some studies have shown that DHA prevents placental apoptosis; therefore, it would reduce preeclampsia, since DHA alone is believed to be more effective as antioxidant and anti-inflammatory medication than its association with EPA [30,31]. The supplementation of pregnant women with omega 3 appears to be associated with increased placental DHA concentration, but not with increased placental EPA. This finding suggests that placental EPA levels can be regulated regardless of maternal levels, a fact that leads to differences in the uptake, accumulation or transfer of these fatty acids to the placenta [32].

Thus, assumingly, the herein observed differences may be associated with the concentration of fatty acids in the formulations provided to patients. Omega formulations used in the current study presented different DHA:EPA ratios-studies have shown that DHA is a better inflammation modulator than EPA [33]. Therefore, the EPA:DHA ratio (2.5:1) did not appear to be effective. Pulsatility indices were lower when the DHA/EPA ratio was 5:1, although it did not represent statistical significance. Therefore, based on the assumption that other ratios may have significant effect on the evaluated variables, our research group will keep on investigating in order to find the best ratio.

The optimal omega 3 dose is also an issue that has not yet been solved. The current study used the dose of 400 mg of omega 3, on average. Studies have shown that the omega curve appears to be U-shaped; thus, low or high doses may weaken omega’s antiinflammatory action. Therefore, selecting an optimal omega 3 remains an open question. Olafsdottir et al. [34] have evaluated the risk of pregnancy-induced hypertension (PIH) and preeclampsia in a population presenting high intake of cod liver oil rich in long-chain polyunsaturated fatty acids (LCPUFA)- their best results were recorded for the intake of 100 to 900 mg of omega 3/day. These results are consistent with the ones reported by Clausen et al. [35], who found that high PUFA intake was associated with increased risk of preeclampsia development. In addition, one cannot neglect that maternal, placental and/or fetal metabolism can present significant interindividual differences. Thus, the best dose to achieve the best result may vary, but it appears that the omega 3 dose used in the current study was adequate [34].

With respect to secondary outcomes, the comparison between ASA use in association, or not, with omega did not show difference in PE, prematurity, oligohydramnios, IUGR or hospitalization in neonatal ICU frequency–results were not statistically significant. Based on the comparison between birth weights, the weight of babies born from mother treated with Omega+ASA was higher (3,167.5 ± 95.4 g) that that of babies born from mothers treated only with ASA (3,109.0 ± 48,094 g), although the difference was not statistically significant (p=0.85) [35]. However, the current research was a pilot study; thus, it is necessary increasing the number of patients to fully assess these results. It is worth highlighting that the study did not record any complications, such as bleedings and thrombocytopenia, caused by the Omega+ASA association. These data corroborate the study by Offman et al. [36], who did not find major complications resulting from associations such as omega+aspirin and omega+warfarin.

Although some studies have shown the beneficial effects of longchain omega 3 fatty acids in reducing preeclampsia, the current study did not find these benefits and did not evaluate subgroups such as diabetic patients, smokers or pregnant women presenting risk factors for premature labor [37-39]. Assumingly, in addition to individual variations that, in our viewpoint, are harder to be evaluated, the DHA: EPA ratio in the formulation was one of the determining factors of the apparently contradictory results. The present study remains in progress; it is now based on higher omega 3 doses (500 mg/day) and on higher DHA proportion (100%), although without its association with EPA.

Conclusion

Omega 3 use in association with ASA has increased the uterine artery resistance and pulsatility indices of the investigated patients; however, it did not make any difference in primary and secondary outcomes. Assumingly, DHA/EPA ratios were associated with these differences. The present study remains in progress; it is now based on changing omega 3 concentrations and on EPA exclusion from the formulation.

REFERENCES

Citation: Batista AC, Ribeiro BC, Paiva BD, Fernandes LMD, Xavier LC, Arcuri MPF, et al. (2019) The Role Played by Salicylic Acid and Omega 3 in the Placental Vascular Resistance Mechanism: A Pilot Study. Clinics Mother Child Health. 16:333. DOI: 10.35248/2090-7214.19.16.333

Copyright: © 2019 Batista AC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.